ADC Airlines

Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2021 Financial Results and Business Updates

Retrieved on:

Friday, July 30, 2021

ET to report financial results for the second quarter ended June 30, 2021 and provide business updates.

Key Points:

ET to report financial results for the second quarter ended June 30, 2021 and provide business updates.
To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 3876353.
A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com .
The Companys early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Companys Immunosynthen platform.

Retrieved on:

Thursday, March 18, 2021

Although the facility has been fully operational since late 2020, the pandemic delayed the official inauguration of the ADC.

Key Points:

Although the facility has been fully operational since late 2020, the pandemic delayed the official inauguration of the ADC.
Geoff Wild, CEO Atotech, said, The opening of the ADC was an important milestone for our Company.
Atotech, headquartered in Berlin, Germany, is a team of 4,000 experts in over 40 countries generating annual revenues of $1.2billion (2020).
With its well-established innovative strength and industry-leading global TechCenter network, Atotech delivers pioneering solutions combined with unparalleled on-site support for over 9,000 customers worldwide.

Retrieved on:

Friday, February 19, 2021

ET to report financial results for the fourth quarter and year ended December 31, 2020 and provide business updates.

Key Points:

ET to report financial results for the fourth quarter and year ended December 31, 2020 and provide business updates.
To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 2354447.
A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com .
The Companys early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Companys Immunosynthen platform.